GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (NAS:LAB) » Definitions » Owner Earnings per Share (TTM)
中文

Standard BioTools (Standard BioTools) Owner Earnings per Share (TTM)

: -0.81 (As of Dec. 2023)
View and export this data going back to 2011. Start your Free Trial

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Standard BioTools's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-0.81. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Standard BioTools's Owner Earnings per Share (TTM) or its related term are showing as below:



LAB's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Standard BioTools's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.25. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.95. It's PE Ratio ratio for today is At Loss.

Standard BioTools's EPS without NRI for the three months ended in Dec. 2023 was $-0.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.81. It's PE Ratio without NRI ratio for today is At Loss.


Standard BioTools Owner Earnings per Share (TTM) Historical Data

The historical data trend for Standard BioTools's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.95 -0.52 -0.90 -2.48 -0.81

Standard BioTools Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -1.76 -1.08 -0.87 -0.81

Competitive Comparison

For the Diagnostics & Research subindustry, Standard BioTools's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools Price-to-Owner-Earnings Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Standard BioTools's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Price-to-Owner-Earnings falls into.



Standard BioTools Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Standard BioTools's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -74.7
Depreciation, Depletion and Amortization 15.2
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 6.7
Change In Working Capital 1.8
Shares Outstanding (Diluted Average) 79.7

1. Start with "Net Income" from income statement. Standard BioTools's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-74.7 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Standard BioTools's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $15.2 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Standard BioTools's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $6.7 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Standard BioTools's 5-Year Average Maintenance Capital Expenditure = $6.7 Mil

5. "Change In Working Capital" is from cashflow statement. Standard BioTools's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $1.8 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Standard BioTools's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 79.739 Mil.

Standard BioTools's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -74.656 +15.18+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-6.6511775784688+1.787)/79.739
=-0.81

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=2.495/-0.81
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Standard BioTools Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools (Standard BioTools) Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Executives
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black officer: SVP & Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Casdin Partners Fo1-msv, Lp director C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p. director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis officer: SVP Chief Commercial Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim officer: Chief Operating Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm director, officer: President & CEO 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110